LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Larimar Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$2.12+0.14 (+6.80%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
91.9%
95M of 104M shares
Institutional holders
163
33 new, 29 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
8 buys · 0 sales
Net bought $25.72M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Israel A. Englander | 4,966,831 | 5.80% | 13G (passive) amendment | Sep 30, 2025 |
| Opaleye, L.P. | 3,952,409 | 6.17% | 13G (passive) | Apr 9, 2025 |
| Deerfield Management Company, L.P. | 35,667,474 | 34.41% | 13D (active) amendment | Feb 27, 2026 |
| Blue Owl Capital Holdings LP | 10,739,492 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LRMR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 35,606,974 | 34.28% | $108.60M | – | 1.13% |
| Blue Owl Capital Holdings LP | 9,163,157 | 8.82% | $27.95M | +2,043,150 | 4.21% |
| BlackRock, Inc. | 5,678,035 | 5.47% | $17.32M | +1,925,835 | 0.00% |
| Defilade Capital Management, L.P. | 3,670,135 | 3.53% | $11.19M | New | 1.50% |
| Driehaus Capital Management LLC | 3,163,423 | 3.05% | $9.65M | +229,024 | 0.06% |
| Vanguard Capital Management LLC | 2,974,901 | 2.86% | $9.07M | +108,552 | 0.00% |
| Rtw Investments, LP | 2,565,999 | 2.47% | $7.83M | +1,065,999 | 0.07% |
| Aqr Capital Management LLC | 2,371,414 | 2.28% | $7.23M | +1,553,897 | 0.00% |
| Marshall Wace, Llp | 2,012,458 | 1.94% | $6.14M | +1,078,994 | 0.00% |
| DAFNA Capital Management LLC | 2,008,164 | 1.93% | $6.12M | −21,000 | 1.17% |
| Goldman Sachs Group Inc | 1,752,910 | 1.69% | $5.35M | +191,325 | 0.00% |
| Geode Capital Management, LLC | 1,679,003 | 1.62% | $5.12M | +570,242 | 0.00% |
| Qube Research & Technologies Ltd | 1,641,042 | 1.58% | $5.01M | +793,398 | 0.00% |
| Citadel Advisors LLC | 1,456,825 | 1.40% | $4.44M | +937,693 | 0.00% |
| State Street Corp | 1,411,804 | 1.36% | $4.31M | +500,478 | 0.00% |
| Vanguard Portfolio Management LLC | 1,403,172 | 1.35% | $4.28M | +996,614 | 0.00% |
| Woodline Partners LP | 1,400,850 | 1.35% | $4.27M | – | 0.01% |
| Millennium Management LLC | 1,333,037 | 1.28% | $4.07M | −2,292,241 | 0.00% |
| Dimensional Fund Advisors LP | 961,083 | 0.93% | $2.93M | +162,621 | 0.00% |
| FMR LLC | 937,368 | 0.90% | $2.86M | +873,798 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 163 | 95M | 91.9% | 33 / 68 | 41 / 29 | 21M | 14M |
| Q1 2026 | 162 | 88M | 84.5% | 43 / 59 | 41 / 15 | 26M | 8M |
| Q4 2025 | 136 | 73M | 70.0% | 22 / 45 | 44 / 19 | 6M | 18M |
| Q3 2025 | 136 | 86M | 82.3% | 30 / 60 | 26 / 9 | 28M | 4M |
| Q2 2025 | 116 | 62M | 60.1% | 30 / 43 | 24 / 17 | 12M | 10M |
| Q1 2025 | 103 | 61M | 58.6% | 16 / 33 | 32 / 28 | 6M | 8M |
| Q4 2024 | 116 | 63M | 61.1% | 22 / 43 | 33 / 27 | 4M | 4M |
| Q3 2024 | 123 | 64M | 61.9% | 25 / 40 | 35 / 8 | 6M | 4M |
| Q2 2024 | 107 | 65M | 62.9% | 24 / 40 | 34 / 21 | 6M | 4M |
| Q1 2024 | 104 | 64M | 61.4% | 41 / 34 | 22 / 5 | 27M | 2M |
| Q4 2023 | 69 | 40M | 38.1% | 8 / 23 | 25 / 3 | 5M | 1M |
| Q3 2023 | 65 | 39M | 37.3% | 8 / 18 | 24 / 8 | 3M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of LRMR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,206,446 | 2.12% | $6.73M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,724,694 | 1.66% | $5.26M | 0.01% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 814,618 | 0.78% | $2.48M | 0.04% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 757,603 | 0.73% | $2.31M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 726,517 | 0.70% | $2.78M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 699,471 | 0.67% | $2.13M | 0.00% | Jun 30, 2026 |
| Vanguard Explorer Fund | 659,133 | 0.63% | $2.52M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 625,151 | 0.60% | $1.91M | 0.01% | Jun 30, 2026 |
| iShares Biotechnology ETF | 370,517 | 0.36% | $1.13M | 0.01% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 340,789 | 0.33% | $1.30M | 0.01% | Jul 31, 2026 |
| Driehaus Micro Cap Growth Fund | 338,986 | 0.33% | $1.03M | 0.17% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 243,097 | 0.23% | $845.98K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 223,612 | 0.22% | $682.02K | 0.04% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 218,451 | 0.21% | $760.21K | 0.00% | May 31, 2026 |
| JPMorgan Small Cap Value Fund | 183,018 | 0.18% | $558.20K | 0.04% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Carole Ben-Maimon | President and CEO, Director | 399,432 | 0.38% | Jan 27, 2026 |
| Michael Celano | Chief Financial Officer | 215,785 | 0.21% | Jan 27, 2026 |
| Russell Clayton | Chief Medical Officer | 71,443 | 0.07% | Jan 27, 2026 |
| Gopi Shankar | Chief Development Officer | 76,443 | 0.07% | Jan 27, 2026 |
| Thomas Edward Hamilton | Director | 874,231 | 0.84% | Jul 8, 2026 |
| Joseph Truitt | Director | 2,750 | 0.00% | May 20, 2026 |
| James E. Flynn | Director, 10% owner | – | – | May 20, 2026 |
| Deerfield Management Company, L.P. | Director, 10% owner | 1,714,104 | 1.65% | May 20, 2026 |
| Frank E. Thomas | Director | 7,000 | 0.01% | May 20, 2026 |
| Jonathan S. Leff | Director | – | – | May 20, 2026 |
| Jeffrey W. Sherman | Director | 5,000 | 0.00% | May 20, 2026 |
| Deerfield Mgmt HIF, L.P. | Director, 10% owner | 35,606,974 | 34.28% | Mar 2, 2026 |
| Deerfield Healthcare Innovations Fund, L.P. | Director, 10% owner | – | – | Mar 2, 2026 |
| Mgmt L.P. Deerfield | Director, 10% owner | 24,009,751 | 23.11% | Mar 2, 2026 |
| Deerfield Mgmt IV, L.P. | Director, 10% owner | 5,830,249 | 5.61% | Mar 2, 2026 |
| Deerfield Private Design Fund IV, L.P. | Director, 10% owner | – | – | Mar 2, 2026 |
| Deerfield Partners, L.P. | Director, 10% owner | – | – | Mar 2, 2026 |
| Deerfield Mgmt III, L.P. | Director, 10% owner | – | – | Mar 2, 2026 |
| Deerfield Private Design Fund III, L.P. | Director, 10% owner | – | – | Mar 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Thomas Edward Hamilton Director | Jul 6, 2026 | Buy | +50,000 | $3.34 | $167.00K | 714,798 |
| Thomas Edward Hamilton Director | Feb 27, 2026 | Buy | +100,000 | $5.00 | $500.00K | 664,798 |
| Jeffrey W. Sherman Director | Feb 27, 2026 | Buy | +5,000 | $5.00 | $25.00K | 5,000 |
| Frank E. Thomas Director | Feb 27, 2026 | Buy | +5,000 | $5.00 | $25.00K | 7,000 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Feb 27, 2026 | Buy | +1,084,012 | $5.00 | $5.42M | 10,622,957 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Feb 27, 2026 | Buy | +831,978 | $5.00 | $4.16M | 8,153,107 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Feb 27, 2026 | Buy | +2,000,000 | $5.00 | $10.00M | 6,207,982 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Feb 27, 2026 | Buy | +1,084,010 | $5.00 | $5.42M | 10,622,928 |
| Russell Clayton Chief Medical Officer | Jan 26, 2026 | Award | +25,637 | – | – | 71,443 |
| Carole Ben-Maimon President and CEO, Director | Jan 26, 2026 | Award | +100,100 | – | – | 368,276 |
| Gopi Shankar Chief Development Officer | Jan 26, 2026 | Award | +25,637 | – | – | 76,443 |
| Michael Celano Chief Financial Officer | Jan 26, 2026 | Award | +37,604 | – | – | 215,785 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Jul 31, 2025 | Buy | +2,599,932 | $3.20 | $8.32M | 7,321,129 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Jul 31, 2025 | Buy | +3,387,539 | $3.20 | $10.84M | 9,538,945 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Jul 31, 2025 | Buy | +3,387,529 | $3.20 | $10.84M | 9,538,918 |
| Michael Celano Chief Financial Officer | Jan 22, 2025 | Award | +34,185 | – | – | 178,181 |
| Gopi Shankar Chief Development Officer | Jan 22, 2025 | Award | +23,306 | – | – | 50,806 |
| Russell Clayton Chief Medical Officer | Jan 22, 2025 | Award | +23,306 | – | – | 45,806 |
| Carole Ben-Maimon President and CEO, Director | Jan 22, 2025 | Award | +91,000 | – | – | 387,208 |
| Thomas Edward Hamilton Director | Feb 16, 2024 | Buy | +57,208 | $8.74 | $500.00K | 564,798 |
| Mgmt L.P. Deerfield Director, 10% owner | Feb 16, 2024 | Buy | +1,430,205 | $8.74 | $12.50M | 4,207,982 |
| Mgmt L.P. Deerfield Director, 10% owner | Feb 16, 2024 | Buy | +1,430,206 | $8.74 | $12.50M | 6,151,389 |
| Mgmt L.P. Deerfield Director, 10% owner | Feb 16, 2024 | Buy | +1,430,206 | $8.74 | $12.50M | 6,151,406 |
| Frank E. Thomas Director | Feb 14, 2024 | Buy | +2,000 | $11.00 | $22.00K | 2,000 |
| Gopi Shankar Chief Development Officer | Jan 17, 2024 | Award | +22,500 | – | – | 27,500 |
| Russell Clayton Chief Medical Officer | Jan 17, 2024 | Award | +22,500 | – | – | 22,500 |
| Carole Ben-Maimon President and CEO, Director | Jan 17, 2024 | Award | +66,125 | – | – | 332,954 |
| Michael Celano Chief Financial Officer | Jan 17, 2024 | Award | +31,250 | – | – | 143,996 |
| Gopi Shankar Chief Development Officer | Dec 7, 2023 | Buy | +5,000 | $3.73 | $18.65K | 5,000 |
| Joseph Truitt Director | May 17, 2023 | Buy | +2,750 | $3.73 | $10.26K | 2,750 |
| Carole Ben-Maimon President and CEO, Director | May 17, 2023 | Buy | +5,000 | $3.71 | $18.55K | 266,829 |
| Michael Celano Chief Financial Officer | May 17, 2023 | Buy | +5,000 | $3.73 | $18.65K | 112,746 |
| Michael Celano Chief Financial Officer | Jan 31, 2023 | Award | +76,000 | – | – | 107,746 |
| Carole Ben-Maimon President and CEO, Director | Jan 31, 2023 | Award | +205,000 | – | – | 261,829 |
| Thomas Edward Hamilton Director | Sep 16, 2022 | Buy | +317,460 | $3.15 | $1,000.00K | 507,590 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Sep 16, 2022 | Buy | +2,777,777 | $3.15 | $8.75M | 2,777,777 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Sep 16, 2022 | Buy | +2,777,777 | $3.15 | $8.75M | 4,721,197 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Sep 16, 2022 | Buy | +2,777,777 | $3.15 | $8.75M | 4,721,183 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Sep 16, 2022 | Buy | +2,777,777 | $3.15 | $8.75M | 4,721,200 |
| Michael Celano Chief Financial Officer | Sep 16, 2022 | Buy | +31,746 | $3.15 | $100.00K | 31,746 |
| Carole Ben-Maimon President and CEO, Director | Sep 16, 2022 | Buy | +31,746 | $3.15 | $100.00K | 56,829 |
| Deerfield Mgmt IV, L.P. Director, 10% owner | Jun 30, 2021 | Buy | +228,571 | $8.75 | $2.00M | 1,943,423 |
| Deerfield Mgmt IV, L.P. Director, 10% owner | Jun 30, 2021 | Buy | +228,569 | $8.75 | $2.00M | 1,943,406 |
| Deerfield Mgmt IV, L.P. Director, 10% owner | Jun 30, 2021 | Buy | +228,570 | $8.75 | $2.00M | 1,943,420 |
| Thomas Edward Hamilton Director | Jun 30, 2021 | Buy | +56,710 | $8.75 | $496.21K | 190,130 |
| Chondrial Therapeutics Holdings, Llc 10% owner | Jun 26, 2020 | Other | −6,091,242 | – | – | 8 |
| Carole Ben-Maimon President and CEO, Director | Jun 26, 2020 | Other | +25,083 | – | – | 25,083 |
| Thomas Edward Hamilton Director | Jun 26, 2020 | Other | +133,420 | – | – | 133,420 |
| Thomas Edward Hamilton Director | Jun 26, 2020 | Other | +159,433 | – | – | 292,853 |
| Robert J. Perez Director | Jan 24, 2019 | Award | +4,423 | $4.38 | $19.37K | 5,322 |
| John L. Lamattina Director | Jan 24, 2019 | Award | +10,844 | $4.38 | $47.50K | 31,376 |
| Atlas Venture Associates VII, L.P. 10% owner | Jun 29, 2018 | Other | −1,126,546 | – | – | 3,506,184 |
| Atlas Venture Associates VII, L.P. 10% owner | Jun 29, 2018 | Other | −234,321 | – | – | 11 |
| Thomas E. Hughes See Remarks, Director | Jun 28, 2018 | Sale(10b5-1 plan) | −32,000 | $10.00 | $320.00K | 125,247 |
| Thomas E. Hughes See Remarks, Director | Mar 7, 2018 | Sale(10b5-1 plan) | −5,000 | $10.00 | $50.00K | 157,247 |
| Thomas O. Daniel Director | Jan 3, 2018 | Award | +8,687 | $5.18 | $45.00K | 19,452 |
| John L. Lamattina Director | Jan 3, 2018 | Award | +9,169 | $5.18 | $47.50K | 20,532 |
| Frances K. Heller Director | Oct 13, 2017 | Buy | +10,000 | $3.90 | $39.00K | 47,961 |
| Dennis D. Kim Chief Medical Officer | Jul 11, 2017 | Buy | +10,000 | $3.39 | $33.90K | 21,443 |
| Thomas E. Hughes President and CEO, Director | May 11, 2017 | Option exercise | +18,928 | $0.75 | $14.20K | 83,088 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Peter Barrett Officer | Jul 24, 2023 | 8,300 | $26.81K | Jul 24, 2023 | STOCK OPTION EXERCISE |